Clinical Trial Update: Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

A neoadjuvant chemoradiotherapy study combining CRLX-101 with capecitabine for rectal cancer was terminated; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• CRLX-101
• Capecitabine (capecitabine)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Rectal Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2017-11-14